These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 30146942)
1. Structural insights into the inhibitor binding and new inhibitor design to Polo-like kinase-1 Polo-box domain using computational studies. Abdullah M; Guruprasad L J Biomol Struct Dyn; 2019 Aug; 37(13):3410-3421. PubMed ID: 30146942 [TBL] [Abstract][Full Text] [Related]
2. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors. Yun T; Qin T; Liu Y; Lai L Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392 [TBL] [Abstract][Full Text] [Related]
3. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy. Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685 [TBL] [Abstract][Full Text] [Related]
4. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors. Sakkiah S; Senese S; Yang Q; Lee KW; Torres JZ PLoS One; 2014; 9(7):e101405. PubMed ID: 25036740 [TBL] [Abstract][Full Text] [Related]
5. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1. Chen Y; Li Z; Liu Y; Lin T; Sun H; Yang D; Jiang C Bioorg Chem; 2018 Dec; 81():278-288. PubMed ID: 30170276 [TBL] [Abstract][Full Text] [Related]
6. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach. Shafique S; Bibi N; Rashid S J Theor Biol; 2016 Jan; 388():72-84. PubMed ID: 26493360 [TBL] [Abstract][Full Text] [Related]
8. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain. Yan F; Liu G; Chen T; Fu X; Niu MM Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137 [TBL] [Abstract][Full Text] [Related]
9. Rational Molecular Design of Potent PLK1 PBD Domain-binding Phosphopeptides Using Preferential Amino Acid Building Blocks. Mao XL; Wang KF; Zhu F; Pan ZH; Wu GM; Zhu HY Chem Biodivers; 2016 Aug; 13(8):1103-10. PubMed ID: 27450535 [TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1. Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362 [TBL] [Abstract][Full Text] [Related]
11. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. Shan HM; Shi Y; Quan J ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850 [TBL] [Abstract][Full Text] [Related]
12. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1. Ryu S; Park JE; Ham YJ; Lim DC; Kwiatkowski NP; Kim DH; Bhunia D; Kim ND; Yaffe MB; Son W; Kim N; Choi TI; Swain P; Kim CH; Lee JY; Gray NS; Lee KS; Sim T J Med Chem; 2022 Feb; 65(3):1915-1932. PubMed ID: 35029981 [TBL] [Abstract][Full Text] [Related]
13. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479 [TBL] [Abstract][Full Text] [Related]
14. Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation. Huggins DJ; McKenzie GJ; Robinson DD; Narváez AJ; Hardwick B; Roberts-Thomson M; Venkitaraman AR; Grant GH; Payne MC PLoS Comput Biol; 2010 Aug; 6(8):. PubMed ID: 20711360 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design. Zhou Y; Yan F; Huo X; Niu MM Molecules; 2019 Nov; 24(23):. PubMed ID: 31795214 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1. Berg A; Berg T Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918 [TBL] [Abstract][Full Text] [Related]
17. Putative Anti-Cancer Drug Candidate Targeting the 'PLK-1-Polo-Box Domain' by High Throughput Virtual Screening: A Computational Drug Design Study. Shakil S; Abuzinadah MF Crit Rev Eukaryot Gene Expr; 2019; 29(3):251-261. PubMed ID: 31679235 [TBL] [Abstract][Full Text] [Related]
18. A case study from the chemistry core of the Pittsburgh Molecular Library Screening Center: the Polo-like kinase polo-box domain (Plk1-PBD). Wipf P; Arnold D; Carter K; Dong S; Johnston PA; Sharlow E; Lazo JS; Huryn D Curr Top Med Chem; 2009; 9(13):1194-205. PubMed ID: 19807663 [TBL] [Abstract][Full Text] [Related]
19. Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain. Zhao XZ; Hymel D; Burke TR Bioorg Med Chem Lett; 2016 Oct; 26(20):5009-5012. PubMed ID: 27624074 [TBL] [Abstract][Full Text] [Related]
20. Identification of potential Plk1 targets in a cell-cycle specific proteome through structural dynamics of kinase and Polo box-mediated interactions. Bibi N; Parveen Z; Rashid S PLoS One; 2013; 8(8):e70843. PubMed ID: 23967120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]